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ABSTRACT: Porous graphitic carbon (PGC) is an important
tool in a chromatographer’s armory that retains polar
compounds with mass spectrometry (MS)-compatible sol-
vents. However, its applicability is severely limited by an
unpredictable loss of retention, which can be attributed to
contamination. The solutions offered fail to restore the original
retention and our observations of retention time shifts of
gemcitabine/metabolites on PGC are not consistent with contamination. The mobile phase affects the ionization state of analytes
and the polarizable PGC surface that influences the strength of dispersive forces governing retention on the stationary phase. We
hypothesized that failure to maintain the same PGC surface before and after running a gradient is a cause of the observed
retention loss/variability on PGC. Herein, we optimize the choice of mobile phase solvent in a gradient program with three parts:
a preparatory phase, which allows binding of analytes to column; an elution phase, which gives the required separation/peak
shape; and a maintenance phase, to preserve the required retention capacity. Via liquid chromatography/tandem mass
spectrometry (LC-MS/MS) analysis of gemcitabine and its metabolites extracted from tumor tissue, we demonstrate
reproducible chromatography on three PGC columns of different ages. This approach simplifies use of the PGC to the same level
as that of a C-18 column, removes the need for column regeneration, and minimizes run times, thus allowing PGC columns to be
used to their full potential.
There are well-known challenges posed by chromatographicseparation of polar compounds such as nucleosides and
nucleotides with subsequent detection by mass spectrometry
(MS).1,2 Equally well documented are the drawbacks of
possible solutions such as MS contamination (e.g., when
using ion-pairing reagents) and reduced sensitivity.1,3 Chroma-
tographic methods can be developed on porous graphitic
carbon (PGC) using MS-compatible solvents that resolve
nucleosides and nucleotides with excellent peak shapes.4,5
However, we and others have reported variability and a general
loss of retention on PGC within a run and over a period of time
that can limit its use.6−9 While hydrophilic interaction liquid
chromatography (HILIC) can offer a useful alternative, its
applications do not always overlap with those of PGC, so PGC
remains an important tool for the chromatography of polar
compounds.
The general loss of retention on PGC is thought to be mainly
due to the column’s particularly high susceptibility to
contamination,7 hence the suggestion to backflush regularly.
Wash procedures involve the use of strong acids/bases and
solvents such as tetrahydrofuran, acetone, trifluoroacetate,
hydrochloric acid, and sodium hydroxide.7,10,11 In addition to
contamination, the column’s capacity for redox reactions has
been cited as an important contributor to variability of
retention and poor peak shape. Preconditioning of the column
with buffered hydrogen peroxide has been shown to prevent a
loss of retention, because of reduction of the stationary
phase.7,9 All these treatments add a significant amount of time
to sample analysis and involve the use of significant volumes of
hazardous chemicals but fail to restore the original retention.
Thus, there is a need to better understand the mechanisms
underlying analyte retention and to simplify robust method
development on PGC.
A detailed description of PGC and the hitherto known
mechanisms of retention have been well-reviewed elsewhere.12
Retention is thought to occur through a combination of factors
with interactions between the mobile phase and analytes
promoting or discouraging retention. Forces such as hydrogen
bonds (that keep analytes in solution) discourage retention. On
the other hand, hydrophobic interactions promote retention by
pushing analytes out of solution toward the PGC surface.
Nonpolar analytes interact with the PGC surface via dispersive
forces while polar ones are retained via charge induction on the
polarizable PGC surface. The mobile phase is a major
determinant of retention because it influences the ionization
state of both analytes and the PGC surface.13 We hypothesized
that failure to maintain the same PGC surface before and after
running a gradient is a cause of the observed retention loss/
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variability on PGC. We now report a method for robust
maintenance of retention capacity of gemcitabine and its
metabolites on PGC through careful selection of the mobile
phase and sequence in a gradient elution program that obviates
the need for washing.
■ EXPERIMENTAL SECTION
Reagents and Chemicals. Acetonitrile, methanol, water
(HPLC grade), and ammonium hydroxide were purchased
from Fisher Scientific (U.K.). Ammonium acetate (LC-MS
grade) and CTP−15N2,13C were obtained from Sigma (U.K.).
Gemcitabine (2′,2′-difluoro-2′-deoxycytidine, dFdC), was
purchased from Tocris, while its metabolites2′,2′-difluoro-
2′-deoxyuridine (dFdU), gemcitabine 5′-triphosphate
(dFdCTP), gemcitabine 5′-diphosphate choline (GdPC),14
stable labeled dFdU−13C,15N2, dFdC−13C,15N2, citicoline-d9
were purchased from Toronto Research Chemicals (Toronto,
Canada).
Instrumentation. Samples were injected using a CTC PAL
HTS-xt autosampler (CTC Analytics AG, Switzerland) with
two wash stations: solvent 1 (50% methanol in water) and
solvent 2 (water). Chromatography was performed with an
Accela pump (Thermo Fisher Scientific, USA). Tandem mass
spectrometry (MS/MS) analysis was performed using a TSQ
Vantage triple-stage quadrupole mass spectrometer (Thermo
Scientific, USA) fitted with a heated electrospray ionization
(HESI-II) probe operated in positive and negative mode at a
spray voltage of 2.5 kV, a capillary temperature of 150 °C, and a
vaporizer temperature of 250 °C. Sheath and auxiliary gas
pressures were set at 50 and 20 units, respectively. Quantitative
data acquisition was performed using LC Quan2.5.6 (Thermo
Fisher Scientific, USA). The MS scan parameters have been
described previously.6,14
Chromatography. PGC Hypercarb (100 mm × 2.1 mm,
ID 5 μm; Thermo Fisher Scientific) columns were kept at 40
°C and fitted with a guard column (Hypercarb, 10 mm × 2.1
mm, 5 μm; Thermo Fisher Scientific). Three different PGC
columns were tested, each of which had previously been used
for a period of 1−3 years.
Gemcitabine (dFdC) and its metabolitesdFdU, dFdCTP,
and GdPC (200 ng/mL of each analyte)were spiked into
tumor tissue homogenate prepared from MIA PaCa-2
xenografts and extracted as previously described.6 The
repeatability of retention and peak shape was assessed for 95
injections.
Repeatability of retention time was also assessed for
gemcitabine and dFdU (spiked in water) on an Acquity
UPLC T3 C-18 column (50 mm × 2.1 mm, ID 1.8 μm;
Waters) maintained at 40 °C (for comparison with PGC).
dFdCTP and GdPC are not retained on the C18 column and,
therefore, were not analyzed. The gradient elution program
comprised mobile phase A (0.1% formate in water) and mobile
phase B (0.1% formate in 100% acetonitrile) at a flow rate of
200 μL/min. The gradient was initiated with 100% A for 1 min,
followed by an increase over 1 min to 70% of B and back to
100% A over another minute. An additional minute of 100% A
completed the gradient to give a total run time of 4 min.
■ RESULTS AND DISCUSSION
Lack of Consistent Retention on PGC with Previous
Methods. Problems with previous methods start when a new
column is exposed to mobile phases other than methanol:water
((95:5), hereafter referred to as 95% methanol), which may
modify the surface of the stationary phase resulting in altered
retention properties. This causes failure to get reproducible
retention from one injection to the next, or on two different
columns with the same method (see Tables S1 and S2 in the
Supporting Information). Two papers by Jansen et al.4,9
illustrate this: despite treating the columns with precondition-
ing buffer containing 0.05% hydrogen peroxide, the retention
time of gemcitabine between the two studies differed by 2.73
min. Our previous gradient elution program (Figure S1 in the
Supporting Information), which had at least 5% acetonitrile
throughout,6 suffered from the same problems; gemcitabine
retention capacity slowly reduced and limited the number of
samples that could be analyzed in one batch. This meant that
after approximately every 50 samples regeneration of the PGC
column was required. This involved inversion and back-flushing
with 50% tetrahydrofuran (THF), 0.1% trifluoroacetic acid
(TFA), then 50% THF plus 0.1% sodium hydroxide, then
water, then re-equilibration with 95% methanol prior to reuse.
Development of the Chromatography. We hypothe-
sized that understanding PGC surface-altering interactions of
different mobile phases would enable development of a method
that maintained the same PGC surface before and after each
sample, standardizing the retention time. Polar analytes interact
with the surface of the stationary phase via charge-induced
interactions, while nonpolar analytes interact via dispersive
forces whose strength may be affected by charge induction
caused by the mobile phase.13 The PGC surface may be
charged due to the effects of mobile phase pH on ionizable
functional groups.13 In addition, the mobile phase may be
involved in electron lone-pair interactions with the electron
cloud of graphite15 that may expose analyte-retaining charge on
the PGC surface. However, it is not clear if the mobile phase
must be adsorbed to be involved in electron lone-pair
interactions with the surface of the stationary phase. Therefore,
a switch from one mobile phase to another may cause a
fundamental change to the column’s surface resulting in a
modification of retention. The extent of modification of the
surface would be dependent on the mobile phases involved. A
new PGC column comes stored in 95% methanol and using
this as a mobile phase should ensure maintenance of retention
without the need for any column regeneration. The hypothesis
was tested by analysis of gemcitabine (dFdC) and three of its
metabolites.
Under isocratic conditions (95% methanol) however, only
dFdC and dFdU were retained and eluted from the column.
dFdCTP and GdPC may have eluted together with the column
void volume (Figure S2A in the Supporting Information). We
reasoned that, consistent with previous studies,15,16 charge
induction on the PGC by methanol could have occurred via its
two electron lone pairs interacting with the electron cloud of
graphite, resulting in the exposure of some positive charge on
the column. Increasing pH would ensure ionization of the
phosphate groups that could be important for retention of
dFdCTP and, to a lesser extent, GdPC. Indeed, a switch to 10
mM ammonium acetate (pH 10) (pH adjusted using
ammonium hydroxide) in 95% methanol resulted in retention
of all four analytes (dFdC, dFdU, dFdCTP, and GdPC) on
PGC (Figure S2B in the Supporting Information). In an
attempt to increase retention further and to improve peak
shape particularly for dFdCTP and GdPC, the percentage of
methanol was reduced from 95% to 70% (Figure S3A in the
Supporting Information) and finally to 50% (Figure S3B in the
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Supporting Information). Reducing the methanol concentra-
tion resulted in increased retention, but the peaks became
broader. In order to increase retention and to make the peaks
sharper, a gradient elution program was then tested.
Designing a Gradient Elution Program with a
Maintenance Step. According to our hypothesis, water with
its two electron lone pairs could interact with the graphite
electrons in a manner similar to that of methanol. Adjusting the
pH to 10 would also ensure maintenance of the negative charge
on the phosphate groups of dFdCTP and GdPC. Therefore,
water would be an excellent part of the preparatory phase,
because it would allow binding of all analytes to the column.
The second part of the gradient focused on elution of the
analytes and, for this, we used acetonitrile to disrupt the charge
induced by water and compete for dispersive interactions with
the PGC surface. The acetonitrile gradient was optimized to
give excellent peak shapes, and a final step of 95% methanol (in
water) was added to ensure maintenance of the original
retention capacity. The optimal elution gradient is shown in
Figure 1.
Analytical Runs. Analytical runs on PGC are notorious for
very long equilibration times, with some groups reporting times
up to 2 h,17 while others had to precondition the column using
an acidic buffer before starting a run.9 In this study, an
analytical run was started by ensuring the original methanol-
specific retention capacity (running 95% methanol at 150 μL/
min for just 5 min). This was followed by an equilibration of
the column for only 2.5 min with mobile phase A (10 mM
ammonium acetate pH 10 in water). The retention time
stabilized after just one injection. Use of the mobile phases as
shown in Figure 1 maintained retention capacity from one
sample to the next, with typical peak shapes demonstrated in
Figure 2. Thus, there was no need for additional steps such as
injecting formic acid between each sample, which others have
used to correct for loss of retention.9 The number of samples
one can run on a PGC column before losing retention/peak
shape has been a big issue; Jansen et al.9 were able to maintain
retention for 60 injections, but this necessitated the use of
hydrogen peroxide. Performance of our method was tested by
extracting the analytes from tumor tissue homogenate and 95
injections were run on each of three different PGC columns of
varying age and usage (over 3 years). Over the 95 injections,
peak shape and retention were maintained: the maximum
standard deviation for retention time was ±0.03 min for all four
analytes on all three columns (coefficient of variation <1%)
(see Table 1).
In order to test how this gradient on PGC compared to the
performance of a C-18 column using the same pump, a method
was set up on an Acquity T3 C-18 column for gemcitabine and
dFdU only (because the phosphorylated metabolites dFdCTP
and GdPC are not retained on the C-18 column, eluting in the
column void volume) (see Figure S-4 in the Supporting
Information). Comparing Figure S-4 with Figure 2 and Table 1
indicates that the PGC is just as robust as a C-18 column with
excellent peak shapes, with the added advantage of being able
to retain dFdCTP and GdPC.
Use of Mobile Phases Other Than 95% Methanol for
the Maintenance Step. The use of a 95% methanol
maintenance step enables the performance of a column to be
consistent over time, so that a column then only needs to be
replaced due to a genuine deterioration in performance and not
a reversible modification of its surface by a solvent other than
95% methanol. The column maintenance step could potentially
be done using any suitable mobile phase and not just 95%
methanol. We predicted that water would interact with the
PGC surface in a similar way to methanol, so its impact on
reproducibility of the chromatography was tested by replacing
methanol with water in the maintenance step (solution C in
Figure 1). Reproducible chromatography was obtained with
water, but with slightly longer retention times than with 95%
methanol (see Table S-3 in the Supporting Information). Using
acetonitrile in the maintenance step did not work: dFdCTP and
GdPC were no longer retained, illustrating the importance of
choosing the correct mobile phase to use in a gradient elution
program.
■ CONCLUSION
In conclusion, we have developed a liquid chromatography
method on porous graphitic carbon (PGC) that overcomes a
key challenge of variable retention and loss of retention. We
applied the approach to analysis of gemcitabine and its
metabolites 2′,2′-difluoro-2′-deoxyuridine (dFdU), gemcitabine
5′-triphosphate (dFdCTP), and gemcitabine 5′-diphosphate
choline (GdPC). The class of nucleoside and nucleotide
compounds has been of interest to bioanalysts for decades,
because of their therapeutic uses as anticancer drugs (e.g.,
gemcitabine, cytarabine, capecitabine) and antiviral drugs (e.g.,
zidovudine, acyclovir). More recently, the importance of having
robust methods for quantifying endogenous nucleotides and
nucleosides has increased, because of a developing body of
literature, demonstrating their roles in epigenetic control of
gene expression18−20 and immune responses.21 The approach
that we have described will allow such molecules to be
quantified by liquid chromatography/tandem mass spectrom-
etry (LC-MS/MS) in a robust and reproducible manner
without the need for ion-pairing reagents. Identification of the
correct mobile phase sequence in a gradient elution program
that ensures analytes interact with the same stationary phase
with every injection is key to maintaining reproducible
Figure 1. Gradient elution program on the PGC column (100 mm ×
2.1 mm, ID 5 μm) thermostated at 40 °C. The mobile phase at a flow
rate of 0.3 mL/min consisted of (A) 10 mM ammonium acetate, pH
10; (B) 100% acetonitrile; and (C) 95% methanol, 5% water.
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retention on PGC. We believe methanol modifies the PGC
surface (probably via electron lone-pair interaction with the
graphite), allowing consistent analyte retention, indicating that
methanol should form the preparatory and maintenance phases.
Water is predicted to interact similarly with the PGC surface
and may be used in place of methanol (although, in our
example, retention times were longer with water). This
approach simplifies use of the PGC to the same level as that
of a C-18 column, removes the need for column regeneration,
minimizes run times, and thus allows PGC columns to be used
to their full potential.
■ ASSOCIATED CONTENT
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Average retention times and number of runs on PGC as
reported by others (Table S1); average retention times
on different PGC columns (age/usage) and the same
column after regeneration, as reported by others (Table
S2); average retention times of gemcitabine and
metabolites on PGC when water replaces 95% methanol
in the column maintenance step (Table S3); gradient
elution program from our previously published method6
(Figure S1); effect on retention and peak shape of
changing from an isocratic mobile phase of 95%
methanol to 10 mM ammonium acetate pH 10 in 95%
methanol (Figure S2); effect on retention and peak shape
of reducing methanol concentration (Figure S3); and
Figure 2. Chemical structures and typical chromatograms, on PGC, of dFdC, dFdU, GdPC, and dFdCTP (200 ng/mL) spiked and extracted from
tumor homogenate, separated using the gradient shown in Figure 1 and detected following heated electrospray ionization using a triple-stage
quadrupole mass spectrometer.
Table 1. Average Retention Times (tR (min)) and Standard
Deviation of 95 Injections of dFdC and Its Metabolites
Extracted from Tumor Homogenate on Three Different
PGC Columns, Using the Gradient Shown in Figure 1,
Detected Following Heated Electrospray Ionization Using a
Triple-Stage Quadrupole Mass Spectrometer
Average Retention Time, tR (min)
dFdC dFdU GdPC dFdCTP
Column No. 10170107
5.09 ± 0.02 4.83 ± 0.02 3.93 ± 0.02 3.62 ± 0.03
Column No. 0610524 V6
5.06 ± 0.03 4.86 ± 0.02 3.92 ± 0.03 3.65 ± 0.02
Column No.: 10065922
5.14 ± 0.02 4.81 ± 0.02 3.91 ± 0.03 3.61 ± 0.03
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typical chromatogram and average retention from a C18
column (Figure S4) (PDF)
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